12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALG889: Began Phase I trial

Allergene Inc., San Mateo, Calif.
Product: ALG889
Business: Infectious diseases
Therapeutic category: Immune modulation
Target: T cells
Description: T cell receptor peptide immunomodulator

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >